
1028 Section XII • Vascular
STEP 4: POSTOPERATIVE CARE
◆ The patient should be admitted for an overnight stay. The potential problems are fever, fl uid
overload, and disseminated intravascular coagulation (DIC). Fever is usually transient and
treated symptomatically. The identifi cation of infection occurs in approximately 5% of those
patients with fever and warrants treatment. Pulmonary edema occurs in approximately 10%
of the patients but usually can be handled with diuretics. DIC is usually subclinical and can
be treated expectantly. The worst case scenario is fulminant bleeding, which requires re-
moval of the shunt. The bleeding may be related to exposure of the systemic circulation to
fi brin split products (FSP)–rich ascitic fl uid that may activate the coagulation mechanism.
Bleeding complications do not appear to be related to the severity of the post-shunt coagu-
lopathy but rather to the severity of liver dysfunction and presence of preoperative DIC,
probably caused by the liver disease.
STEP 5: PEARLS AND PITFALLS
◆ The contraindications for shunt insertion should include pseudomyxoma peritonei, recent
or current infection, preoperative coagulopathy, liver failure, and loculated ascites. Relative
contraindications include positive cytologic fi ndings in ascitic fl uid and concurrent cardiac
failure. Bloody ascites and ascitic fl uid protein content greater than 4.5 g/L are also consid-
ered contraindications to shunting, secondary to increased risk of shunt blockage from clot
or fi brin plugs.
◆ If a patient has had episodes of variceal bleeding, the risk of rebleeding postshunt is great
secondary to the risk of postshunt coagulopathy and increased intravascular volume.
SELECTED REFERENCES
1. Smith EM, Jayson GC: The current and future management of malignant ascites. Clin Oncol
(R Coll Radiol) 2003;15:59-72.
2. Becker G, Galandi D, Blum HE: Malignant ascites: Systematic review and guideline for treatment.
Eur J Cancer 2006;42:589-597.
3. Suzuki H, Stanley AJ: Current management and novel therapeutic strategies for refractory ascites and
hepatorenal syndrome. QJM 2001;94:293-300.